Department of Visceral Surgery, University Hospital CHUV, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Liver Surgery, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
HPB (Oxford). 2023 Jul;25(7):836-844. doi: 10.1016/j.hpb.2023.04.001. Epub 2023 Apr 9.
According to the Barcelona Clinic Liver Cancer (BCLC) staging system, liver resection (LR) is recommended for early-stage (BCLC-A) hepatocellular carcinoma (HCC) but not for intermediate-stage (BCLC-B). This study aimed to assess the outcomes of LR in these patients using a subclassification tumour burden score (TBS).
All consecutive patients that underwent LR for BCLC-A and BCLC-B HCC between 01/2010 and 12/2020 in 4 tertiary referral centers were included. Clinical outcomes and overall survival (OS) were assessed in relation to TBS and BCLC stages.
Among 612 patients included, 562 were classified as BCLC-A and 50 as BCLC-B. The incidence of overall postoperative complications (56.0 vs 41.5%, p = 0.053) and mortality (0 vs 1.6%, p = 1.000) were similar between BCLC-A and BCLC-B patients. OS was significantly higher for BCLC A/low TBS than BCLC B/low TBS (p = 0.009), while patients with medium and high TBS had similar OS, irrespective of BCLC stage (respectively p = 0.103 and p = 0.343).
Patients with medium and high TBS had comparable OS and DFS, irrespective of BCLC A or B stage, and postoperative morbidity was comparable. These results highlight the need for refinement of the BCLC staging system, and LR could be considered for selected intermediate stage (BCLC-B) according to the tumour burden.
根据巴塞罗那临床肝癌(BCLC)分期系统,肝切除术(LR)推荐用于早期(BCLC-A)肝细胞癌(HCC),但不适用于中期(BCLC-B)。本研究旨在使用肿瘤负荷评分(TBS)评估这些患者接受 LR 的结果。
纳入了 2010 年 1 月至 2020 年 12 月在 4 家三级转诊中心接受 LR 治疗的所有连续 BCLC-A 和 BCLC-B HCC 患者。评估了 TBS 和 BCLC 分期与临床结果和总生存期(OS)的关系。
在纳入的 612 例患者中,562 例被分类为 BCLC-A,50 例被分类为 BCLC-B。整体术后并发症发生率(56.0%比 41.5%,p=0.053)和死亡率(0 比 1.6%,p=1.000)在 BCLC-A 和 BCLC-B 患者之间相似。BCLC A/低 TBS 的 OS 明显高于 BCLC B/低 TBS(p=0.009),而中高 TBS 患者的 OS 相似,与 BCLC 分期无关(分别为 p=0.103 和 p=0.343)。
中高 TBS 患者无论 BCLC A 或 B 期,其 OS 和DFS 相当,术后发病率相当。这些结果强调了需要改进 BCLC 分期系统,并且可以根据肿瘤负荷考虑将 LR 用于选定的中期(BCLC-B)。